A recent retrospective analysis published in Cardiology and Therapy indicates that the PRECISE-DAPT score, originally designed to assess bleeding risk after percutaneous coronary intervention, may also serve as a valid predictor of mid-term all-cause mortality in patients with acute coronary syndrome. The study, conducted at the University Hospital Královské Vinohrady in Prague, Czech Republic, analyzed data from 2,953 patients hospitalized between October 2018 and October 2023. The researchers aimed to validate the score’s utility beyond its traditional scope of identifying high bleeding risk, specifically examining its correlation with survival outcomes over a mean follow-up period of 1.9 years.
The PRECISE-DAPT score is a clinical tool that incorporates several patient-specific variables, including age, creatinine clearance, hemoglobin levels, white blood cell count, and history of spontaneous bleeding. In current European Society of Cardiology guidelines, a score of 25 or higher is used to define high bleeding risk in patients undergoing percutaneous coronary intervention. While previous studies have explored the score’s ability to predict bleeding complications in acute coronary syndrome and after coronary bypass grafting, its role in predicting overall long-term prognosis has been less extensively documented. This study sought to clarify whether the standard threshold of 25 could effectively stratify mortality risk across different subtypes of acute coronary syndrome and varying antithrombotic treatment strategies.
The study population consisted of 2,953 patients with a complete clinical dataset necessary for calculating the PRECISE-DAPT score. The cohort was predominantly male, with 69.1% of patients being men. The mean age of the participants was 67.4 years, with a standard deviation of 12.5 years. The breakdown of acute coronary syndrome subtypes included 37.1% with ST-elevation myocardial infarction, 45.2% with non-ST-elevation myocardial infarction, and 17.7% with unstable angina pectoris. A total of 78.4% of the patients were treated with percutaneous coronary intervention, while the remainder underwent coronary bypass grafting or conservative management.
Researchers utilized receiver operating characteristic curve analysis to assess the predictive performance of the PRECISE-DAPT score for mortality. The area under the curve was calculated for each acute coronary syndrome subtype to quantify the score’s discrimination ability, with higher values indicating better prediction. The results demonstrated that the PRECISE-DAPT score had the strongest predictive ability in patients with ST-elevation myocardial infarction, achieving an area under the curve of 0.84, with a 95% confidence interval ranging from 0.82 to 0.87. For patients with non-ST-elevation myocardial infarction, the area under the curve was 0.78, and for those with unstable angina pectoris, it was 0.75.
The study also examined the impact of the antithrombotic treatment strategy at discharge on the score’s predictive validity. Patients were categorized into three groups based on their discharge regimen: dual antiplatelet therapy, dual antithrombotic therapy, and triple therapy. Dual antiplatelet therapy involved a combination of acetylsalicylic acid and a P2Y12 inhibitor, such as ticagrelor, prasugrel, or clopidogrel. Dual antithrombotic therapy combined a single antiplatelet agent with anticoagulation treatment, while triple therapy included acetylsalicylic acid, a P2Y12 inhibitor, and an anticoagulation agent. The analysis revealed that the antithrombotic treatment strategy did not significantly influence the predictive ability of the PRECISE-DAPT score, with areas under the curve of 0.78, 0.71, and 0.72 for the respective groups.
Mortality rates were significantly higher among patients with a PRECISE-DAPT score of 25 or higher compared to those with scores below 25. In-hospital mortality was 11.6% for the high-score group versus 1.1% for the low-score group. Mid-term all-cause mortality, assessed over the 1.9-year follow-up period, was 42.5% for patients with a score of 25 or higher, compared to 10.0% for those with lower scores. These differences were statistically significant, with a p-value of less than 0.0001. The study noted that patients in the higher score group tended to be older, had more complex coronary disease, additional comorbidities, and were in a higher Killip class at admission, all of which are factors associated with worse outcomes.
The researchers also compared the predictive performance of the score based on the revascularization strategy used. There was no significant difference in mortality prediction between patients treated with percutaneous coronary intervention and those treated with coronary bypass grafting, with areas under the curve of 0.803 and 0.804, respectively. This finding suggests that the prognostic value of the PRECISE-DAPT score remains consistent regardless of the specific revascularization method employed, supporting its potential use as a universal prognostic tool in acute coronary syndrome management.
Limitations of the study include its single-center design and retrospective nature, which restricted the analysis to all-cause mortality and precluded the assessment of specific ischemic or bleeding events. The information on antithrombotic treatment was based on discharge recommendations, which may have changed during the follow-up period. Additionally, the number of patients receiving dual antithrombotic therapy and triple therapy was limited, which may affect the generalizability of the results for these specific groups. The authors emphasize that a larger, multi-center analysis would be necessary to confirm these findings and further validate the score’s utility in diverse clinical settings.
The study contributes to the growing body of evidence suggesting that the PRECISE-DAPT score has broader prognostic implications than previously recognized. While it was initially developed to guide the duration of antiplatelet therapy by identifying patients at high risk of bleeding, its ability to predict mid-term mortality in acute coronary syndrome patients offers a new perspective for risk stratification. The consistency of the score’s predictive power across different antithrombotic strategies and revascularization methods underscores its robustness as a clinical tool.
In conclusion, the PRECISE-DAPT score with a standard threshold of 25 maintains acceptable prognostic performance for predicting mid-term all-cause mortality in acute coronary syndrome, with the best predictive ability observed in ST-elevation myocardial infarction. The score’s utility appears to be independent of the antithrombotic treatment strategy at discharge, suggesting its potential as a versatile tool for risk stratification in this patient population. Further validation in larger cohorts is warranted to establish its role in routine clinical practice.
The PRECISE-DAPT score was originally developed to predict bleeding complications in patients undergoing percutaneous coronary intervention who require dual antiplatelet therapy. The scoring model integrates specific clinical and laboratory data, including age, creatinine clearance, hemoglobin levels, white blood cell count, and a history of previous spontaneous bleeding. European Society of Cardiology guidelines currently recommend the score to identify patients at high bleeding risk, a category defined by a score of 25 or higher. While the score has been validated for predicting bleeding events in acute coronary syndrome and after coronary bypass grafting, its application for predicting overall long-term prognosis in these patient populations has been less extensively documented. This study specifically investigated whether the standard threshold could serve as a prognostic indicator for all-cause mortality across different acute coronary syndrome subtypes and treatment regimens.
The research team established a prospective acute coronary syndrome registry at the University Hospital Královské Vinohrady Cardiocentre in Prague, Czech Republic, in 2018. The study analyzed all patients hospitalized for acute coronary syndrome over a five-year period, from October 2018 to October 2023. Initially, 3,127 patients were hospitalized for the condition. Researchers excluded 123 patients diagnosed with myocardial infarction with non-obstructive coronary arteries and 54 patients who lacked available major clinical and anamnestic data. A listwise deletion method was applied to handle missing data, resulting in a final cohort of 2,953 patients who possessed a complete clinical dataset necessary for calculating the PRECISE-DAPT score. Mortality data were collected in cooperation with the Institute of Health Information and Statistics of the Czech Republic, with the date of censoring set at December 31, 2024.
The study compared the standard PRECISE-DAPT score threshold of 25 or higher with survival outcomes. Patients with a score of 25 or higher were over 15 years older on average than those with lower scores. This higher-score group also presented with more complex coronary disease, additional comorbidities, and a higher Killip class at admission. These clinical factors are associated with worse outcomes and may contribute to the observed mortality differences. The researchers noted that the reliability of the threshold is supported by the apparent differences between the groups, suggesting that the score effectively stratifies patients based on their overall clinical burden and risk profile.
The authors compared their findings with previous research to contextualize the predictive performance of the score. A recent study by Ando et al. involving 552 patients with myocardial infarction treated by percutaneous coronary intervention reported a mean follow-up of 1,424 days. In that study, the PRECISE-DAPT score predicted mortality with an area under the curve of 0.78. The current study demonstrated a better discrimination value for ST-elevation myocardial infarction, suggesting it may be a more appropriate subgroup for prognostication using this score. The researchers hypothesize that these results highlight bleeding as a prominent risk factor in ST-elevation myocardial infarction patients, who constitute the youngest group with the least comorbidities in this analysis.
The study also examined the influence of revascularization strategy on the score’s prognostic role. The researchers found that the choice between percutaneous coronary intervention and coronary bypass grafting did not significantly influence the predictive ability of the PRECISE-DAPT score. Although both strategies pose different risks during the initial hospitalization, the influence of the revascularization strategy on bleeding appears to diminish in the long term. This finding aligns with previous investigations by Enström et al., who concluded that the score can be used for prognostication in coronary bypass grafting patients regardless of different antithrombotic strategies. The consistency of the score’s performance across these different treatment pathways supports its potential utility as a universal prognostic tool in acute coronary syndrome management.
Subject of Research: Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies
Article Title: Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies
Article References: Bauer, D., Fojtík, A., Berka, V., Neuberg, M., Kočka, V., Prachtová, R., & Toušek, P. (2026). Prognostic Role of the PRECISE-DAPT Score in Acute Coronary Syndrome and Different Antithrombotic Treatment Strategies. Cardiology and Therapy, 15(1), 123-133. https://doi.org/10.1007/s40119-026-00444-w
Image Credits: AI Generated
DOI: 10.1007/s40119-026-00444-w
Keywords: Prognostic, Role, PRECISE-DAPT, Score, Acute, Coronary, Syndrome, Different, Antithrombotic, Treatment, Strategies, scientific research
News Source: Ophelia Keating. (November 10, 2026). PRECISE-DAPT Score Predicts Mortality in Acute Coronary Syndrome. Scienmag.



